{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode'])) Logout @endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

Evaluation of treatment approaches for suspected underactive bladder (UAB): Clinical preference and patient outcomes

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Current Practice Patterns

  1. What are the primary causes of Underactive Bladder you observe in your practice? (Select all that apply) *

  2. What are your current preferences for treatment of underactive bladder? *

  3. How does Bethanechol fit into your treatment landscape for underactive bladder? *

  4. How is Bethanechol integrated into your treatment protocol for urinary retention? *

  5. If you use bethanechol in combination with other therapies, please specify which therapies you commonly combine it with: *
  6. What are the preferred indications for usage of Bethanechol in management of UAB? (Select all that apply) *

  7. What is your preference for using bethanechol in patients with UAB associated with diabetic neuropathy? *

  8. What is your preferred dose and schedule of Bethanechol for adult patients? *
    9. Dose (select one) Dosing schedule (select one)

    {{-- --}}

    {{-- --}}

    {{-- --}}

  9. In what clinical scenarios do you find it most beneficial to prescribe 50 mg of Bethanechol for managing UAB, and what specific patient characteristics influence this decision? *
  10. What factors lead you to choose a dosage of 75 mg SR of Bethanechol over 50 mg/25 mg in your treatment of UAB? *
  11. On a scale of 1 to 3, how would you rate the efficacy of Bethanechol in treating Underactive Bladder? *

  12. What are the most common side effects observed with Bethanechol in your practice (Select all that apply)? *

  13. What are the current challenges do you face when managing patients with UAB? *
  14. What key communication points about bethanechol do you find most impactful? *
  15. What is your preferred approach to prescribing Bethanechol for managing UAB in specific patient profiles (e.g., BPH, post-operative, diabetes), including whether you consider it a first-line, second-line, or non-preferred option? *
  16. Additionally, do you typically use Bethanechol alone or in combination with alpha-blockers or clean intermittent catheterization (CIC)? *
  17. What are your preferred dosages of Bethanechol and treatment durations for managing the above conditions? *